Here are five things to know:
1. The new Stretta RFT3 maintains the same procedure as the first two generations of Stretta, however its features aesthetic, functional, and material improvements.
2. Stretta technology is intended to help treat chronic those suffering from gastroesophageal reflux disease.
3. The new technology will be launched at Digestive Disease Week 2016, May 21-24 in San Diego.
4. At Digestive Disease Week, Mark Noar, MD, director of The Heartburn and Reflux Study Center in Towson, Md., will discuss 10-year follow-up data on Stretta from studies he conducted.
5. Mederi Therapeutics manufactures non-surgical devices that use non-ablative radiofrequency energy to treat digestive diseases.
More articles on GI/endoscopy:
5 most read GI/endoscopy stories: April 25 – April 29
American Academy of Arts and Sciences elects Dr. John Carethers: 4 things to know
Tobira Therapeutics’ drug safe for obese patients with health issues: 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.